Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Cediranib with Standard Therapy for SCLC
NCT02899728Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, cediranib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Mar 2018; status: terminated.
02
Drugs
olaparibcediranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02899728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899728.